Company news
NFL Biosciences SA news in 2026
NFL Biosciences SA's news releases, calls and decks from 2026, newest first.
NFL Biosciences will participate in the BIO-Europe 2026 conference to continue discussions with potential partners regarding NFL-101 and NFL-102
October 29, 2026
NFL Biosciences Reports Its 2026 Half-Year Results and Progress With Its Two Immunotherapies for Smoking and Nicotine Cessation
October 21, 2026
NFL Biosciences Receives Regulatory Approval to Begin Its Phase 2 TONIC Trial for Smoking and Nicotine Cessation
October 21, 2026
NFL Biosciences: Progress Update Ahead of Upcoming Value-Creating Milestones for Its Two Clinical Programs in Smoking Cessation
October 6, 2026
NFL Biosciences to Present Its Personalized Medicine Approach to Smoking Cessation at the 20th Congress of the Société Francophone de Tabacologie
September 8, 2026
NFL Biosciences Submits an Application for Authorization of the Phase 2 TONIC Clinical Trial Evaluating NFL-102 in Smoking Cessation
July 28, 2026
International Scientific Recognition for NFL Biosciences: 3 Presentations Selected at the 2026 SRNT-Europe Conference, Including an Oral Presentation on NFL-102
July 7, 2026
NFL Biosciences Announces the Successful Manufacturing of a GMP Clinical Batch of NFL-102 and Validates Its Industrial Production Chain
June 30, 2026
NFL Biosciences Releases New Results on NFL-101 and Reaffirms Its Personalized Approach to Smoking Cessation
June 1, 2026
NFL Biosciences Is Strengthening Its Personalized Medicine Approach to Smoking Cessation With a New Patent Application
May 25, 2026
NFL Biosciences Clarifies the Objectives and Evaluation Criteria for a Predictive Biomarker Associated With NFL-101
May 11, 2026
NFL Biosciences: International Scientific Community’s Interest in NFL-102 for Smoking Cessation Confirmed by the Selection of Its Work at Two Leading Conferences
May 4, 2026
NFL Biosciences Presents Its 2025 Annual Results and Provides an Update on Its Clinical Progress Driven by a New Paradigm in Smoking Cessation
April 15, 2026
NFL Biosciences Strengthens Its Cash Position by €2.6 Million Through Bond Financing Subscribed by a Group of European Institutional Investors
April 15, 2026
A New Paradigm in Tobacco and Nicotine Addiction: NFL Biosciences Demonstrates the Mechanism of Action of NFL-102 in a Video
April 7, 2026
Bpifrance Renews Its Confidence in NFL Biosciences Through the Granting of a €500,000 Loan
March 11, 2026
NFL Biosciences Publishes Its 2026 Financial Agenda
February 19, 2026
NFL Biosciences Significantly Raises Its Efficacy Targets for Smoking Cessation
January 26, 2026